Raymond James Financial
REGN icon

Raymond James Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Raymond James Financial’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108M Buy
172,896
+7,354
+4% +$5.01M 0.03% 532
2026
Q1 		$128M Buy
165,542
+15,932
+11% +$12.2M 0.04% 420
2025
Q4 		$115M Buy
149,610
+11,104
+8% +$7.54M 0.04% 449
2025
Q3 		$77.9M Buy
138,506
+7,455
+6% +$4.22M 0.03% 584
2025
Q2 		$68.8M Buy
131,051
+19,542
+18% +$10.9M 0.02% 604
2025
Q1 		$70.7M Buy
111,509
+20,006
+22% +$13.8M 0.03% 557
2024
Q4 		$65.2M Buy
+91,503
New +$76.8M 0.02% 593

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Raymond James Financial's REGN Position: Q2 2026 in Review

Raymond James Financial increased its Regeneron Pharmaceuticals (REGN) stake by 4.4% in Q2 2026, buying an estimated $5.01M and bringing the position to 172,896 shares worth $108M. The position accounts for 0.03% of the portfolio, ranked #532.

Raymond James Financial first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $128M in Q1 2026. 1,339 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Raymond James Financial held 172,896 shares of Regeneron Pharmaceuticals worth $108M as of Q2 2026.
  • Raymond James Financial bought 7,354 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $5.01M.
  • Regeneron Pharmaceuticals made up 0.03% of Raymond James Financial's portfolio in Q2 2026, its #532 holding.
  • Raymond James Financial first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Regeneron Pharmaceuticals position peaked at $128M in Q1 2026.
  • 1,339 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.